One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

The firms will evaluate two adjuvant treatment options, Datroway with rilvegostomig or rilvegostomig monotherapy, against standard-of-care treatment.

A MUM has shared a shocking photo of a giant lump protruding from her breast, which doctors repeatedly dismissed a benign.

During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the fourth quarter of 2024. Core earnings ...